Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 1, 2010, Pages 103-120

  Deryugina, Elena I ^a   Quigley, James P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenic switch; Cancer; FGF 2; Matrix metalloproteinases; Metastasis; MMP 9; Neutrophil; Tumor angiogenesis; VEGF

Indexed keywords

COLLAGENASE 3; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; STROMELYSIN 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

B LYMPHOCYTE; BASEMENT MEMBRANE; BIOAVAILABILITY; CARCINOGENESIS; CARCINOMA; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CHONDROSARCOMA; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CARCINOMA; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; STEM CELL; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CARCINOMA;

ANIMALS; ENZYME ACTIVATION; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; STEM CELLS;

EID: 77049108176     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.09.017     Document Type: Review

References (240)

1. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
2. Eichmann A., Pardanaud L., Yuan L., Moyon D. Vasculogenesis and the search for the hemangioblast. J. Hematother. Stem Cell Res. 2002, 11:207-214.
3. Tang D.G., Conti C.J. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update. Semin. Thromb. Hemost. 2004, 30:109-117.
4. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
5. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
7. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev., Cancer 2007, 7:800-808.
8. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
9. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
10. Papaspyridonos M., Lyden D. Chapter 11. The role of bone marrow-derived cells in tumor angiogenesis and metastatic progression. Methods Enzymol. 2008, 444:255-269.
11. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 2000, 156:361-381.
12. McDonald D.M., Foss A.J. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev. 2000, 19:109-120.
13. Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26:717-724.
14. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev., Immunol. 2004, 4:617-629.
15. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007, 26:587-596.
16. van Hinsbergh V.W., Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 2008, 78:203-212.
17. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., Cancer 2003, 3:401-410.
18. Zucker S., Lysik R.M., Zarrabi M.H., Stetler-Stevenson W., Liotta L.A., Birkedal-Hansen H., Mann W., Furie M. Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol. Biomark. Prev. 1992, 1:475-479.
19. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999, 13:1382-1397.
20. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
21. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., Fidler I.J. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 2002, 94:1134-1142.
22. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 2004, 114:623-633.
23. Pahler J.C., Tazzyman S., Erez N., Chen Y.Y., Murdoch C., Nozawa H., Lewis C.E., Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
24. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
25. Jodele S., Chantrain C.F., Blavier L., Lutzko C., Crooks G.M., Shimada H., Coussens L.M., Declerck Y.A. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005, 65:3200-3208.
26. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12493-12498.
27. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
28. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
29. Martin M.D., Carter K.J., Jean-Philippe S.R., Chang M., Mobashery S., Thiolloy S., Lynch C.C., Matrisian L.M., Fingleton B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 2008, 68:6251-6259.
30. Masson V., de la Ballina L.R., Munaut C., Wielockx B., Jost M., Maillard C., Blacher S., Bajou K., Itoh T., Itohara S., Werb Z., Libert C., Foidart J.M., Noel A. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005, 19:234-236.
31. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3884-3889.
32. Jodele S., Blavier L., Yoon J.M., DeClerck Y.A. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
33. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
34. Nielsen B.S., Sehested M., Kjeldsen L., Borregaard N., Rygaard J., Dano K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab. Invest. 1997, 77:345-355.
35. van Kempen L.C., de Visser K.E., Coussens L.M. Inflammation, proteases and cancer. Eur. J. Cancer 2006, 42:728-734.
36. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev., Cancer 2004, 4:71-78.
37. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
38. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 2006, 80:1183-1196.
39. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009.
40. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
41. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
42. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2108-2114.
43. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
44. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
45. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
46. Deryugina E.I., Quigley J.P. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem. Cell. Biol. 2008, 130:1119-1130.
47. Van Den Steen P.E., Wuyts A., Husson S.J., Proost P., Van Damme J., Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 2003, 270:3739-3749.
48. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20262-20267.
49. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., Proost P., Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 2001, 69:851-859.
50. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37:375-536.
51. Acuff H.B., Carter K.J., Fingleton B., Gorden D.L., Matrisian L.M. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res. 2006, 66:259-266.
52. Heissig B., Rafii S., Akiyama H., Ohki Y., Sato Y., Rafael T., Zhu Z., Hicklin D.J., Okumura K., Ogawa H., Werb Z., Hattori K. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J. Exp. Med. 2005, 202:739-750.
53. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., Pennington C.J., Bourgoin P., Edwards D.R., Yong V.W. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
54. Owen J.L., Iragavarapu-Charyulu V., Lopez D.M. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe?. Breast Dis. 2004, 20:145-153.
55. Wolf K., Muller R., Borgmann S., Brocker E.B., Friedl P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 2003, 102:3262-3269.
56. Gaudin P., Trocme C., Berthier S., Kieffer S., Boutonnat J., Lamy C., Surla A., Garin J., Morel F. TIMP-1/MMP-9 imbalance in an EBV-immortalized B lymphocyte cellular model: evidence for TIMP-1 multifunctional properties. Biochim. Biophys. Acta. 2000, 1499:19-33.
57. Yakubenko V.P., Lobb R.R., Plow E.F., Ugarova T.P. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp. Cell Res. 2000, 260:73-84.
58. Di Girolamo N., Tedla N., Lloyd A., Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur. J. Immunol. 1998, 28:1773-1784.
59. Owen J.L., Iragavarapu-Charyulu V., Gunja-Smith Z., Herbert L.M., Grosso J.F., Lopez D.M. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J. Immunol. 2003, 171:4340-4351.
60. Kay N.E. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk. Res. 2004, 28:221-222.
61. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
62. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
63. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
64. Stuelten C.H., DaCosta Byfield S., Arany P.R., Karpova T.S., Stetler-Stevenson W.G., Roberts A.B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J. Cell. Sci. 2005, 118:2143-2153.
65. Sabeh F., Ota I., Holmbeck K., Birkedal-Hansen H., Soloway P., Balbin M., Lopez-Otin C., Shapiro S., Inada M., Krane S., Allen E., Chung D., Weiss S.J. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 2004, 167:769-781.
66. Rowe R.G., Li X.Y., Hu Y., Saunders T.L., Virtanen I., Garcia de Herreros A., Becker K.F., Ingvarsen S., Engelholm L.H., Bommer G.T., Fearon E.R., Weiss S.J. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J. Cell Biol. 2009, 184:399-408.
67. Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002, 70:561-573.
68. Saunders W.B., Bohnsack B.L., Faske J.B., Anthis N.J., Bayless K.J., Hirschi K.K., Davis G.E. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J. Cell Biol. 2006, 175:179-191.
69. Galvez B.G., Genis L., Matias-Roman S., Oblander S.A., Tryggvason K., Apte S.S., Arroyo A.G. Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. J. Biol. Chem. 2005, 280:1292-1298.
70. Iruela-Arispe M.L., Davis G.E. Cellular and molecular mechanisms of vascular lumen formation. Dev. Cell 2009, 16:222-231.
71. Chun T.H., Sabeh F., Ota I., Murphy H., McDonagh K.T., Holmbeck K., Birkedal-Hansen H., Allen E.D., Weiss S.J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 2004, 167:757-767.
72. Yana I., Sagara H., Takaki S., Takatsu K., Nakamura K., Nakao K., Katsuki M., Taniguchi S., Aoki T., Sato H., Weiss S.J., Seiki M. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell. Sci. 2007, 120:1607-1614.
73. Gerhardt H., Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003, 314:15-23.
74. Collett G.D., Canfield A.E. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ. Res. 2005, 96:930-938.
75. Chantrain C.F., Henriet P., Jodele S., Emonard H., Feron O., Courtoy P.J., DeClerck Y.A., Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur. J. Cancer 2006, 42:310-318.
76. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., Werb Z., Coussens L.M., DeClerck Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004, 64:1675-1686.
77. Lehti K., Allen E., Birkedal-Hansen H., Holmbeck K., Miyake Y., Chun T.H., Weiss S.J. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev. 2005, 19:979-991.
78. Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999, 107:38-44.
79. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
80. Cao J., Rehemtulla A., Bahou W., Zucker S. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J. Biol. Chem. 1996, 271:30174-30180.
81. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4052-4057.
82. Wang Z., Juttermann R., Soloway P.D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 2000, 275:26411-26415.
83. Holmbeck K., Bianco P., Yamada S., Birkedal-Hansen H. MT1-MMP: a tethered collagenase. J. Cell. Physiol. 2004, 200:11-19.
84. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 1999, 274:13066-13076.
85. Pfeifer A., Kessler T., Silletti S., Cheresh D.A., Verma I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12227-12232.
86. Lombard C., Saulnier J., Wallach J. Assays of matrix metalloproteinases (MMPs) activities: a review. Biochimie 2005, 87:265-272.
87. Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003, 63:5224-5229.
88. George S.J., Johnson J.L. In situ zymography. Methods Mol. Biol. 2001, 151:411-415.
89. Yan S.J., Blomme E.A. In situ zymography: a molecular pathology technique to 1649 localize endogenous protease activity in tissue sections. Vet. Pathol. 2003, 40:227-236.
90. Frederiks W.M., Mook O.R. Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases: review and protocols. J. Histochem. Cytochem. 2004, 52:711-722.
91. Sloane B.F., Sameni M., Podgorski I., Cavallo-Medved D., Moin K. Functional imaging of tumor proteolysis. Annu. Rev. Pharmacol. Toxicol. 2006, 46:301-315.
92. Xu J., Rodriguez D., Petitclerc E., Kim J.J., Hangai M., Moon Y.S., Davis G.E., Brooks P.C. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 2001, 154:1069-1079.
93. Hangai M., Kitaya N., Xu J., Chan C.K., Kim J.J., Werb Z., Ryan S.J., Brooks P.C. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. 2002, 161:1429-1437.
94. Cretu A., Roth J.M., Caunt M., Akalu A., Policarpio D., Formenti S., Gagne P., Liebes L., Brooks P.C. Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin. Cancer Res. 2007, 13:3068-3078.
95. Akalu A., Roth J.M., Caunt M., Policarpio D., Liebes L., Brooks P.C. Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin. Cancer Res. 2007, 67:4353-4363.
96. Ramos-DeSimone N., Moll U.M., Quigley J.P., French D.L. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma 1993, 12:349-363.
97. Pelus L.M., Bian H., King A.G., Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 2004, 103:110-119.
98. Hobson J.P., Liu S., Rono B., Leppla S.H., Bugge T.H. Imaging specific cell-surface proteolytic activity in single living cells. Nat. Methods 2006, 3:259-261.
99. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Brocker E.B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
100. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., Stack M.S., Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
101. Packard B.Z., Artym V.V., Komoriya A., Yamada K.M. Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol. 2009, 28:3-10.
102. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev., Cancer 2003, 3:362-374.
103. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
104. Cravatt B.F., Wright A.T., Kozarich J.W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 2008, 77:383-414.
105. Dix M.M., Simon G.M., Cravatt B.F. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell 2008, 134:679-691.
106. Morrison C.J., Butler G.S., Rodriguez D., Overall C.M. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 2009.
107. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev., Cancer 2002, 2:161-174.
108. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell. Biol. 2007, 8:221-233.
109. Lopez-Otin C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283:30433-30437.
110. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16:558-564.
111. Brooks P.C., Lin J.M., French D.L., Quigley J.P. Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis. J. Cell Biol. 1993, 122:1351-1359.
112. Xu J., Rodriguez D., Kim J.J., Brooks P.C. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 2000, 19:375-385.
113. Schenk S., Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol. 2003, 13:366-375.
114. Ponce M.L., Hibino S., Lebioda A.M., Mochizuki M., Nomizu M., Kleinman H.K. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res. 2003, 63:5060-5064.
115. Itoh Y., Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 2006, 206:1-8.
116. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J., Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45.
117. Genis L., Galvez B.G., Gonzalo P., Arroyo A.G. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev. 2006, 25:77-86.
118. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
119. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev., Cancer 2003, 3:453-458.
120. Sounni N.E., Roghi C., Chabottaux V., Janssen M., Munaut C., Maquoi E., Galvez B.G., Gilles C., Frankenne F., Murphy G., Foidart J.M., Noel A. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 2004, 279:13564-13574.
121. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev., Cancer 2003, 3:422-433.
122. Davis G.E., Senger D.R. Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Curr. Opin. Hematol. 2008, 15:197-203.
123. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C., Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
124. Goerge T., Barg A., Schnaeker E.M., Poppelmann B., Shpacovitch V., Rattenholl A., Maaser C., Luger T.A., Steinhoff M., Schneider S.W. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006, 66:7766-7774.
125. Blackburn J.S., Brinckerhoff C.E. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am. J. Pathol. 2008, 173:1736-1746.
126. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
127. Ratnikov B.I., Rozanov D.V., Postnova T.I., Baciu P.G., Zhang H., DiScipio R.G., Chestukhina G.G., Smith J.W., Deryugina E.I., Strongin A.Y. An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J. Biol. Chem. 2002, 277:7377-7385.
128. Brooks P.C., Silletti S., von Schalscha T.L., Friedlander M., Cheresh D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92:391-400.
129. Deryugina E.I., Ratnikov B.I., Postnova T.I., Rozanov D.V., Strongin A.Y. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J. Biol. Chem. 2002, 277:9749-9756.
130. Basile J.R., Holmbeck K., Bugge T.H., Gutkind J.S. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem. 2007, 282:6899-6905.
131. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12485-12490.
132. Kong D., Li Y., Wang Z., Banerjee S., Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007, 67:3310-3319.
133. Ohno-Matsui K., Uetama T., Yoshida T., Hayano M., Itoh T., Morita I., Mochizuki M. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest. Ophthalmol. Vis. Sci. 2003, 44:5370-5375.
134. Dean R.A., Butler G.S., Hamma-Kourbali Y., Delbe J., Brigstock D.R., Courty J., Overall C.M. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell. Biol. 2007, 27:8454-8465.
135. Dean R.A., Overall C.M. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol. Cell. Proteomics 2007, 6:611-623.
136. Deryugina E.I., Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 2002, 62:580-588.
137. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002, 16:555-564.
138. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005, 169:681-691.
139. Tobe T., Ortega S., Luna J.D., Ozaki H., Okamoto N., Derevjanik N.L., Vinores S.A., Basilico C., Campochiaro P.A. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 1998, 153:1641-1646.
140. Ozaki H., Okamoto N., Ortega S., Chang M., Ozaki K., Sadda S., Vinores M.A., Derevjanik N., Zack D.J., Basilico C., Campochiaro P.A. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am. J. Pathol. 1998, 153:757-765.
141. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev. 1997, 18:26-45.
142. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
143. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I., Quigley J.P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J. Biol. Chem. 2009, 284:25854-25866.
144. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
145. Sanderson R.D., Yang Y., Kelly T., MacLeod V., Dai Y., Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem. 2005, 96:897-905.
146. Tholozan F.M., Gribbon C., Li Z., Goldberg M.W., Prescott A.R., McKie N., Quinlan R.A. FGF-2 release from the lens capsule by MMP-2 maintains lens epithelial cell viability. Mol. Biol. Cell. 2007, 18:4222-4231.
147. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
148. Ribatti D., Presta M. The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. J. Cell. Mol. Med. 2002, 6:439-446.
149. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
150. Handsley M.M., Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 2005, 115:849-860.
151. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005, 65:3967-3979.
152. Cornelius L.A., Nehring L.C., Harding E., Bolanowski M., Welgus H.G., Kobayashi D.K., Pierce R.A., Shapiro S.D. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 1998, 161:6845-6852.
153. Gorrin-Rivas M.J., Arii S., Furutani M., Mizumoto M., Mori A., Hanaki K., Maeda M., Furuyama H., Kondo Y., Imamura M. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin. Cancer Res. 2000, 6:1647-1654.
154. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2202-2207.
155. Pozzi A., LeVine W.F., Gardner H.A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002, 21:272-281.
156. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
157. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486:247-251.
158. Heljasvaara R., Nyberg P., Luostarinen J., Parikka M., Heikkila P., Rehn M., Sorsa T., Salo T., Pihlajaniemi T. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp. Cell Res. 2005, 307:292-304.
159. Wickstrom S.A., Alitalo K., Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002, 62:5580-5589.
160. Hamano Y., Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 2005, 333:292-298.
161. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
162. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
163. Deryugina E.I., Bourdon M.A., Jungwirth K., Smith J.W., Strongin A.Y. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int. J. Cancer 2000, 86:15-23.
164. Deryugina E.I., Ratnikov B., Monosov E., Postnova T.I., DiScipio R., Smith J.W., Strongin A.Y. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 2001, 263:209-223.
165. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999, 13:35-48.
166. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
167. Fridman R., Toth M., Chvyrkova I., Meroueh S.O., Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 2003, 22:153-166.
168. Mira E., Lacalle R.A., Buesa J.M., de Buitrago G.G., Jimenez-Baranda S., Gomez-Mouton C., Martinez A.C., Manes S. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J. Cell. Sci. 2004, 117:1847-1857.
169. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18:3964-3972.
170. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
171. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9:702-712.
172. Rafii S., Lyden D. Cancer. A few to flip the angiogenic switch. Science 2008, 319:163-164.
173. Rafii S., Avecilla S., Shmelkov S., Shido K., Tejada R., Moore M.A., Heissig B., Hattori K. Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann. N. Y. Acad. Sci. 2003, 996:49-60.
174. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev., Cancer 2002, 2:826-835.
175. De Palma M., Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim. Biophys. Acta 2006, 1766:159-166.
176. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
177. Seandel M., Butler J., Lyden D., Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 2008, 13:181-183.
178. Kiel M.J., Yilmaz O.H., Iwashita T., Terhorst C., Morrison S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005, 121:1109-1121.
179. Larrivee B., Niessen K., Pollet I., Corbel S.Y., Long M., Rossi F.M., Olive P.L., Karsan A. Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J. Immunol. 2005, 175:2890-2899.
180. Kaplan R.N., Rafii S., Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006, 66:11089-11093.
181. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
182. Van den Steen P.E., Proost P., Grillet B., Brand D.D., Kang A.H., Van Damme J., Opdenakker G. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 2002, 16:379-389.
183. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., Hynes R.O., Werb Z., Sudhakar A., Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
184. Tazzyman S., Lewis C.E., Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int. J. Exp. Pathol. 2009, 90:222-231.
185. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev., Cancer 2008, 8:592-603.
186. Seandel M., Noack-Kunnmann K., Zhu D., Aimes R.T., Quigley J.P. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 2001, 97:2323-2332.
187. Nguyen M., Shing Y., Folkman J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 1994, 47:31-40.
188. Zijlstra A., Aimes R.T., Zhu D., Regazzoni K., Kupriyanova T., Seandel M., Deryugina E.I., Quigley J.P. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J. Biol. Chem. 2004, 279:27633-27645.
189. Zijlstra A., Seandel M., Kupriyanova T.A., Partridge J.J., Madsen M.A., Hahn-Dantona E.A., Quigley J.P., Deryugina E.I. Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. Blood 2006, 107:317-327.
190. Deryugina E.I., Quigley J.P. Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Methods Enzymol. 2008, 444:21-41.
191. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
192. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., Gomis R.R., Manova-Todorova K., Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
193. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
194. Sternlicht M.D., Bissell M.J., Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000, 19:1102-1113.
195. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
196. McCawley L.J., Crawford H.C., King L.E., Mudgett J., Matrisian L.M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004, 64:6965-6972.
197. Wilson C.L., Matrisian L.M. Matrilysin. Matrix Metalloproteinases 1998, 149-184. (Academic Press). W.C. Parks, R.P. Mecham (Eds.).
198. Nishizuka I., Ichikawa Y., Ishikawa T., Kamiyama M., Hasegawa S., Momiyama N., Miyazaki K., Shimada H. Matrix stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo. Cancer Lett. 2001, 173:175-182.
199. Balbin M., Fueyo A., Tester A.M., Pendas A.M., Pitiot A.S., Astudillo A., Overall C.M., Shapiro S.D., Lopez-Otin C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 2003, 35:252-257.
200. Montel V., Kleeman J., Agarwal D., Spinella D., Kawai K., Tarin D. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 2004, 64:1687-1694.
201. Gutierrez-Fernandez A., Inada M., Balbin M., Fueyo A., Pitiot A.S., Astudillo A., Hirose K., Hirata M., Shapiro S.D., Noel A., Werb Z., Krane S.M., Lopez-Otin C., Puente X.S. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 2007, 21:2580-2591.
202. Lin M., Jackson P., Tester A.M., Diaconu E., Overall C.M., Blalock J.E., Pearlman E. Matrix metalloproteinase-8 facilitates neutrophil migration through the corneal stromal matrix by collagen degradation and production of the chemotactic peptide Pro-Gly-Pro. Am. J. Pathol. 2008, 173:144-153.
203. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
204. Nabha S.M., Bonfil R.D., Yamamoto H.A., Belizi A., Wiesner C., Dong Z., Cher M.L. Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. Clin. Exp. Metastasis 2006, 23:335-344.
205. Lakka S.S., Gondi C.S., Yanamandra N., Dinh D.H., Olivero W.C., Gujrati M., Rao J.S. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res. 2003, 63:2454-2461.
206. Lakka S.S., Gondi C.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Rao J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004, 23:4681-4689.
207. Lakka S.S., Gondi C.S., Dinh D.H., Olivero W.C., Gujrati M., Rao V.H., Sioka C., Rao J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J. Biol. Chem. 2005, 280:21882-21892.
208. Dong Z., Kumar R., Yang X., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997, 88:801-810.
209. Acuff H.B., Sinnamon M., Fingleton B., Boone B., Levy S.E., Chen X., Pozzi A., Carbone D.P., Schwartz D.R., Moin K., Sloane B.F., Matrisian L.M. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006, 66:7968-7975.
210. Houghton A.M., Grisolano J.L., Baumann M.L., Kobayashi D.K., Hautamaki R.D., Nehring L.C., Cornelius L.A., Shapiro S.D. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006, 66:6149-6155.
211. Hashimoto G., Inoki I., Fujii Y., Aoki T., Ikeda E., Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 2002, 277:36288-36295.
212. Devy L., Huang L., Naa L., Yanamandra N., Pieters H., Frans N., Chang E., Tao Q., Vanhove M., Lejeune A., van Gool R., Sexton D.J., Kuang G., Rank D., Hogan S., Pazmany C., Ma Y.L., Schoonbroodt S., Nixon A.E., Ladner R.C., Hoet R., Henderikx P., Tenhoor C., Rabbani S.A., Valentino M.L., Wood C.R., Dransfield D.T. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009, 69:1517-1526.
213. Jost M., Folgueras A.R., Frerart F., Pendas A.M., Blacher S., Houard X., Berndt S., Munaut C., Cataldo D., Alvarez J., Melen-Lamalle L., Foidart J.M., Lopez-Otin C., Noel A. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res. 2006, 66:5234-5241.
214. Kolb C., Mauch S., Krawinkel U., Sedlacek R. Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp. Cell Res. 1999, 250:122-130.
215. Pendas A.M., Folgueras A.R., Llano E., Caterina J., Frerard F., Rodriguez F., Astudillo A., Noel A., Birkedal-Hansen H., Lopez-Otin C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell. Biol. 2004, 24:5304-5313.
216. Quesada A.R., Medina M.A., Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. BioEssays 2007, 29:1159-1168.
217. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev., Cancer 2008, 8:579-591.
218. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
219. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
220. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
221. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
222. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
223. Molina J.R., Reid J.M., Erlichman C., Sloan J.A., Furth A., Safgren S.L., Lathia C.D., Alberts S.R. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005, 16:997-1002.
224. Fingleton B. MMP Inhibitor Clinical Trials - The Past, Present, and Future The Cancer Degradome ed al. DEe 2008, Vol Part V:759-785. Springer, New York.
225. Wong S.Y., Hynes R.O. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?. Cell Cycle 2006, 5:812-817.
226. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncol. 2007, 8:444-448.
227. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., De Smet F., Vinckier S., Aragones J., Debackere K., Luttun A., Wyns S., Jordan B., Pisacane A., Gallez B., Lampugnani M.G., Dejana E., Simons M., Ratcliffe P., Maxwell P., Carmeliet P. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
228. Johnson C., Sung H.J., Lessner S.M., Fini M.E., Galis Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ. Res. 2004, 94:262-268.
229. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., Albini A., Bussolino F., Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
230. Vacca A., Ribatti D., Roccaro A.M., Ria R., Palermo L., Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta. Haematol. 2001, 106:162-169.
231. Lafleur M.A., Forsyth P.A., Atkinson S.J., Murphy G., Edwards D.R. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. Biochem. Biophys. Res. Commun. 2001, 282:463-473.
232. Behzadian M.A., Wang X.L., Windsor L.J., Ghaly N., Caldwell R.B. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest. Ophthalmol. Vis. Sci. 2001, 42:853-859.
233. Filippov S., Koenig G.C., Chun T.H., Hotary K.B., Ota I., Bugge T.H., Roberts J.D., Fay W.P., Birkedal-Hansen H., Holmbeck K., Sabeh F., Allen E.D., Weiss S.J. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J. Exp. Med. 2005, 202:663-671.
234. Bremer C., Bredow S., Mahmood U., Weissleder R., Tung C.H. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001, 221:523-529.
235. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., Van Wart H., Poole A.R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997, 99:1534-1545.
236. Carragher N.O. Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover. Clin. Exp. Metastasis 2009, 26:381-397.
237. Yang J., Zhang Z., Lin J., Lu J., Liu B.F., Zeng S., Luo Q. Detection of MMP activity in living cells by a genetically encoded surface-displayed FRET sensor. Biochim. Biophys. Acta 2007, 1773:400-407.
238. Ouyang M., Lu S., Li X.Y., Xu J., Seong J., Giepmans B.N., Shyy J.Y., Weiss S.J., Wang Y. Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging. J. Biol. Chem. 2008, 283:17740-17748.
239. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
240. Rao J.S., Gondi C., Chetty C., Chittivelu S., Joseph P.A., Lakka S.S. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol. Cancer Ther. 2005, 4:1399-1408.